Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | OGA | O60502 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3236636 | 0.85 | SIGMAR1 (0.58) | SIGMAR1KDM4ECYP1A2GAACYP2C9 | |
| SCHEMBL12513634 | 0.78 | SLC6A2 (0.54) | KDM4ECYP1A2MEN1KMT2A | |
| SCHEMBL13561473 | 0.75 | P2RX7 (0.50) | KDM4E | |
| SCHEMBL10845812 | 0.73 | POLB (0.48) | KDM4EDRD2HTR1A | |
| SCHEMBL17897245 | 0.72 | OGA (0.56) | SIGMAR1KDM4ECYP1A2GAACYP2C9 | |
| SCHEMBL9602967 | 0.71 | SIGMAR1 (0.79) | SIGMAR1KDM4ECYP1A2GAACYP2C9 | |
| SCHEMBL20476309 | 0.71 | HRH3 (0.47) | KDM4EMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL10844029 | 0.70 | SIGMAR1 (0.41) | SIGMAR1KDM4ECYP1A2GAACYP2C9 | |
| SCHEMBL24499385 | 0.70 | OGA (0.54) | OGA | |
| Bmy-14802 SCHEMBL8457738 | 0.70 | SIGMAR1 (1.00) | SIGMAR1KDM4ECYP1A2GAACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4994460-A | Treatment or prevention of disorders resulting from central nervous system anoxia | BRISTOL-MYERS SQUIBB CO. (US) | 1991-02-19 | — | — | US | claimed |
| EP-0400661-A1 | Agents for treatment of brain ischemia | Bristol-Myers Squibb Company (US) | 1990-12-05 | — | — | EP | claimed |